NASDAQ:ANL

Adlai Nortye (ANL) Stock Price, News & Analysis

Adlai Nortye logo
$8.55 -0.51 (-5.63%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$8.56 +0.00 (+0.06%)
As of 11/20/2026 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Adlai Nortye Stock (NASDAQ:ANL)

Advanced

Key Stats

Today's Range
$8.36
▼
$9.11
50-Day Range
$8.55
▼
$16.60
52-Week Range
$0.88
▼
$17.25
Volume
380,646 shs
Average Volume
234,923 shs
Market Capitalization
$550.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50
Consensus Rating
Moderate Buy

Company Overview

Adlai Nortye is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2004 and headquartered in Hangzhou, China, the company conducts drug research and development for potential use in China and international markets.

Its investigational oncology pipeline includes AN2025, a pan-RAF inhibitor; AN0025, an EP4 antagonist; and AN4005, an adenosine A2A/A2B receptor antagonist. These candidates are being studied for their potential to treat solid tumors, including in combination with other cancer therapies.

Adlai Nortye’s products are investigational and have not been established as approved treatments. The company’s work centers on advancing its drug candidates through clinical development.

AI Generated. May Contain Errors.

Adlai Nortye Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

ANL MarketRank™: 
1.840960134755 of 5 stars

Adlai Nortye scored higher than 37% of companies evaluated by MarketBeat, and ranked 662nd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adlai Nortye has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Adlai Nortye has a consensus price target of $29.50, representing about 245.0% upside from its current price of $8.55.

  • Amount of Analyst Coverage

    Adlai Nortye has only been the subject of 3 research reports in the past 90 days.

  • Read more about Adlai Nortye's stock forecast and price target.
  • Earnings Growth

    Earnings for Adlai Nortye are expected to decrease in the coming year, from ($0.21) to ($0.36) per share.

  • Percentage of Shares Shorted

    9.00% of the float of Adlai Nortye has been sold short.
  • Short Interest Ratio / Days to Cover

    Adlai Nortye has a short interest ratio ("days to cover") of 27.38, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Adlai Nortye has recently increased by 13.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Adlai Nortye does not currently pay a dividend.

  • Dividend Growth

    Adlai Nortye does not have a long track record of dividend growth.

  • News Sentiment

    Adlai Nortye has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Adlai Nortye this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Adlai Nortye insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $411,060.00 in company stock.

  • Percentage Held by Institutions

    35.21% of the stock of Adlai Nortye is held by institutions.

  • Read more about Adlai Nortye's insider trading history.
Receive ANL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adlai Nortye and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANL Stock News Headlines

ANL - Adlai Nortye Group Ltd.
The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
See More Headlines

ANL Stock Analysis - Frequently Asked Questions

Adlai Nortye's stock was trading at $1.42 at the beginning of the year. Since then, ANL stock has increased by 502.1% and is now trading at $8.55.

Adlai Nortye (ANL) raised $58 million in an initial public offering on Friday, September 29th 2023. The company issued 2,500,000 shares at $23.00 per share.

Top institutional investors of Adlai Nortye include Soleus Capital Management L.P. (1.98%), Marshall Wace LLP (0.12%), State Street Corp (0.06%) and Goldman Sachs Group Inc. (0.05%). Insiders that own company stock include Xiaofeng Ye, Ping Ji and Yang Lu.
View institutional ownership trends
.

Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ANL
Previous Symbol
NASDAQ:ANL
CIK
1944552
Fax
N/A
Employees
109
Year Founded
2004

Price Target and Rating

High Price Target
$49.00
Low Price Target
$20.00
Potential Upside/Downside
+245.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
9.55
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$18.06 million
Price / Sales
30.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.21) per share
Price / Book
-40.71

Miscellaneous

Outstanding Shares
64,398,000
Free Float
N/A
Market Cap
$550.60 million
Optionable
Not Optionable
Beta
1.36

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:ANL) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners